Novartis Ag

Vernalis &r&d) Ltd.

Novartis Pharma Gmbh

Navartis Ag

Vernalis Limited

Michael Mutz

Thomas Schupp

Guido Jordine

Hans Hofmann

Frank Petersen

Klaus Memmert

Marion Mahnke

Brian William Dymock

Martin James Drysdale

Christoph Max Krell

Ernst K&uuml;sters

Holger Petersen

Weijia Zheng

Bernd Koch

Pascale Hoehn

Paul William Manley

Mahavir Prashad

Mika Lindvall

Heinz Ernst Moser

Frank Stowasser

Robert Lowell Simmons

Hans Michael Bürger

Jessica Liang

Ernst Küsters

Zaixing Li

Folkert Reck

Anthony Casarez

Elisabete Goncalves

Bernd Ulrich Riebesehl

Andreas Fisch

Hong-Yong Kim

Weichun Chen

Wolfgang Wirth

Vijay Sethuraman

Christopher Towler

Ruoqiu Wu

Eric Aubin

Marc Schoenhentz

Oskar Kalb

Christoph Krell

The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

Salts and solid forms of a monobactam antibiotic

The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.

Plymorphic forms of deferasirox (ICL670A)

Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterization are disclosed.

Crystalline form K of imatinib mesylate

The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.

Organic compounds

The present invention relates to salts, polymorphs and hydrates of 2-Amino-2-[2-(4-C-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.

Crystalline form F of imatinib mesylate

Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterizations are disclosed.

Crystalline form I of imatinib mesylate

The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.

The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(&#x2212;) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.

Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Crystalline form G of imatinib mesylate

The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.

Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Polymorphic forms of deferasirox (ICL670A)

There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and a method of preparing it.

Quinazolinone derivatives useful as vanilloid antagonists

The invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4-(4 -methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.

Crystal form H imatinib mesylate for pharmaceutical use

The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.

Crystal form of N-benzoyl-staurosporine

Growing community of inventors

Freiburg, Germany

Michael Mutz